Brain Circulation

PERSPECTIVE
Year
: 2022  |  Volume : 8  |  Issue : 4  |  Page : 169--171

Branch atheromatous disease and treatment


Honglian Duan1, Ho Jun Yun2, Xiaokun Geng3, Yuchuan Ding2 
1 Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
2 Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI 48201, USA
3 Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI 48201, USA; Department of Neurology, Luhe Institute of Neuroscience, Capital Medical University, Beijing, China

Correspondence Address:
Xiaokun Geng
Department of Neurology, Beijing Luhe Hospital, Capital Medical University, No. 82 Xinhua South Road, Tongzhou, Beijing 101149

Branch atheromatous disease (BAD) is a subtype of ischemic stroke caused by perforating arteries occlusion due to proximal atherosclerosis of the arteries. Early neurological deterioration and recurrent stereotyped transient ischemic attacks are typical clinical manifestations of BAD. The optimal treatment for BAD has not been determined. This article explores a possible mechanism of BAD and effective treatment measures to prevent early progression and attack of transient ischemic events. This article explains the current status of intravenous thrombolysis, tirofiban, and argatroban for BAD and subsequent prognosis.


How to cite this article:
Duan H, Yun HJ, Geng X, Ding Y. Branch atheromatous disease and treatment.Brain Circ 2022;8:169-171


How to cite this URL:
Duan H, Yun HJ, Geng X, Ding Y. Branch atheromatous disease and treatment. Brain Circ [serial online] 2022 [cited 2023 Feb 1 ];8:169-171
Available from: http://www.braincirculation.org/article.asp?issn=2394-8108;year=2022;volume=8;issue=4;spage=169;epage=171;aulast=Duan;type=0